Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial.
Christiyanti DewiFalerina PuspitaIrma Melyani PuspitasariNeily ZakiyahPublished in: Therapeutics and clinical risk management (2023)
Our analysis concluded that adult gout patients enrolled in the included RCTs exhibited similar hepatic safety profiles for both febuxostat and allopurinol treatment. Liver function abnormalities were identified in all RCTs included in this systematic review. Consequently, it is important for the product labeling information of both allopurinol and febuxostat to present and describe the current safety data to guide healthcare practitioners when prescribing these medications to patients. Pharmacovigilance and post-marketing pharmacoepidemiology data are essential in establishing the comprehensive safety profile.
Keyphrases
- end stage renal disease
- systematic review
- randomized controlled trial
- healthcare
- ejection fraction
- chronic kidney disease
- newly diagnosed
- primary care
- prognostic factors
- peritoneal dialysis
- emergency department
- electronic health record
- young adults
- smoking cessation
- general practice
- combination therapy
- drug induced